Zhejiang Haisen Pharmaceutical Co. Ltd. A
Zhejiang Haisen Pharmaceutical Co., Ltd. engages in the research and development, production, sale, and import and export of pharmaceutical intermediates, active pharmaceutical ingredients, and preparations in China and internationally. The company offers active pharmaceutical ingredients for anti-gastric ulcer, antilipemic agent, antipyretic analgesics, antidepressant, analgesic, cardiovascular,… Read more
Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367) - Net Assets
Latest net assets as of June 2025: CN¥1.40 Billion CNY
Based on the latest financial reports, Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367) has net assets worth CN¥1.40 Billion CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.52 Billion) and total liabilities (CN¥126.36 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.40 Billion |
| % of Total Assets | 91.71% |
| Annual Growth Rate | 54.94% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 70.2 |
Zhejiang Haisen Pharmaceutical Co. Ltd. A - Net Assets Trend (2021–2024)
This chart illustrates how Zhejiang Haisen Pharmaceutical Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Zhejiang Haisen Pharmaceutical Co. Ltd. A (2021–2024)
The table below shows the annual net assets of Zhejiang Haisen Pharmaceutical Co. Ltd. A from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.34 Billion | +7.59% |
| 2023-12-31 | CN¥1.25 Billion | +166.36% |
| 2022-12-31 | CN¥469.03 Million | +29.82% |
| 2021-12-31 | CN¥361.29 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang Haisen Pharmaceutical Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 159.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥451.21 Million | 33.57% |
| Other Components | CN¥892.94 Million | 66.43% |
| Total Equity | CN¥1.34 Billion | 100.00% |
Zhejiang Haisen Pharmaceutical Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Zhejiang Haisen Pharmaceutical Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Titomic Ltd
AU:TTT
|
$146.93 Million |
|
AVY Precision Technology
TWO:5392
|
$146.98 Million |
|
APAC Opto Electronics
TWO:4908
|
$147.09 Million |
|
Cardinal Ethanol LLC
OTCGREY:CRDE
|
$147.10 Million |
|
Suzhou Longjie Special Fiber Co Ltd
SHG:603332
|
$146.89 Million |
|
FIRST SAVINGS FINL DL-01
F:8N4
|
$146.85 Million |
|
Chengdu Shengbang Seals Co.Ltd.
SHE:301233
|
$146.85 Million |
|
Ningbo Tianyi Medical Appliance Co. Ltd.
SHE:301097
|
$146.83 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang Haisen Pharmaceutical Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,249,334,655 to 1,344,154,657, a change of 94,820,002 (7.6%).
- Net income of 122,557,732 contributed positively to equity growth.
- Dividend payments of 34,000,000 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥122.56 Million | +9.12% |
| Dividends Paid | CN¥34.00 Million | -2.53% |
| Other Changes | CN¥6.26 Million | +0.47% |
| Total Change | CN¥- | 7.59% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang Haisen Pharmaceutical Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.62x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 7.16x to 2.62x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | CN¥3.23 | CN¥23.15 | x |
| 2022-12-31 | CN¥4.20 | CN¥23.15 | x |
| 2023-12-31 | CN¥8.39 | CN¥23.15 | x |
| 2024-12-31 | CN¥8.85 | CN¥23.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang Haisen Pharmaceutical Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.12%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 25.99%
- • Asset Turnover: 0.32x
- • Equity Multiplier: 1.11x
- Recent ROE (9.12%) is below the historical average (16.61%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 26.02% | 24.17% | 0.81x | 1.32x | CN¥57.87 Million |
| 2022 | 22.94% | 25.45% | 0.75x | 1.21x | CN¥60.69 Million |
| 2023 | 8.38% | 26.33% | 0.30x | 1.07x | CN¥-20.27 Million |
| 2024 | 9.12% | 25.99% | 0.32x | 1.11x | CN¥-11.86 Million |
Industry Comparison
This section compares Zhejiang Haisen Pharmaceutical Co. Ltd. A's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $1,563,293,604
- Average return on equity (ROE) among peers: -11.65%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367) | CN¥1.40 Billion | 26.02% | 0.09x | $146.91 Million |
| Zhejiang Int'L Group Co Ltd (000411) | $177.19 Million | 13.55% | 0.63x | $201.14 Million |
| Zhejiang Zhenyuan Share Co Ltd (000705) | $280.61 Million | 7.70% | 0.99x | $310.45 Million |
| Hunan Jingfeng Pharmaceutical (000908) | $638.18 Million | -181.03% | 3.22x | $202.85 Million |
| Hubei Guangji Pharmaceutical Co Ltd (000952) | $477.68 Million | 3.28% | 0.64x | $234.89 Million |
| Yifan Xinfu Pharmaceutical Co Ltd (002019) | $9.15 Billion | 2.09% | 0.37x | $1.03 Billion |
| Guangdong Jiaying Pharmaceutical Co Ltd (002198) | $278.08 Million | 2.72% | 0.13x | $459.10 Million |
| Chongqing Lummy Pharmaceutical (300006) | $107.91 Million | 22.70% | 0.99x | $476.38 Million |
| Zhejiang Jolly Pharmaceutical Co Ltd (300181) | $1.44 Billion | 5.91% | 0.29x | $1.19 Billion |
| Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) | $1.53 Billion | 18.22% | 0.05x | $893.48 Million |